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Abstract 
The 2018 Paris Intensive Care symposium entitled “Update in Neurocritical Care” was organized in Paris, June 21–22, 
2018, under the auspices of the French Intensive Care Society. This 2-day post-graduate educational symposium com-
prised several chapters, aiming first to provide all-board intensivists with current standards for the clinical assessment 
of altered consciousness states (including coma and delirium) and peripheral nervous system in critically ill patients, 
monitoring of brain function (specifically, electro-encephalography) and best practices for sedation—analgesia—
delirium management. An update on the treatment of specific severe brain pathologies—including ischaemic/
haemorrhagic stroke, cerebral venous thrombosis, hypoxic-ischaemic brain injury, immune-mediated and infectious 
encephalitis and refractory status epilepticus—was also provided. Finally, we discuss how to approach some difficult 
decisions, namely the role of decompressive craniectomy and prognostication models in patients with head injury. 
For each chapter, the scope of the present review was to provide important issues and key messages, provide most 
recent and relevant literature in the field, and briefly describe new developments in the field.
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Introduction
The 2018 Paris Intensive Care (PIC) symposium organ-
ized in Paris, June 21–22, 2018, under the auspices of the 
French Intensive Care Society focused on neurocritical 
care. This 2-day educational symposium provided gen-
eral intensivists with an overall view of basic principles 
of neurological assessment, neuro-monitoring and seda-
tion management to apply at the bedside when caring for 
the injured brain. Specific severe acute brain pathologies 
were reviewed aiming at providing an update on current 
best practice care of several diseases—such as ischae-
mic/haemorrhagic stroke, cerebral venous thrombosis, 
hypoxic-ischaemic brain injury, immune-mediated and 
infectious encephalitis and refractory status epilepticus. 
We also discussed difficult decisions such as the role of 
decompressive craniectomy and neuro-prognostication 
following head injury. The objective of the present review 
is to summarize, for each chapter, the most important 
issues and key messages (what is important), and briefly 
describe new developments in the field (what is new), 
aiming at providing updated relevant literature in the 
field.
Caring for the injured brain: general aspects
See also Table 1.
Assessment of the comatose patient
What is important
Assessment of the comatose patient relies on clini-
cal examination, neuroimaging and neuro-monitoring. 
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Neurological examination includes the Glasgow Coma 
Scale (GCS)—and particularly the GCS-motor response 
(GCS-M) to pain—and brainstem reflexes, with a specific 
attention to pupillary aspect (symmetry) and functional-
ity (reactivity) [1]. The Full Outline of Unresponsiveness 
(FOUR) score comprises the assessment of both the cor-
tical and brainstem functions [2].
Neuroimaging encompasses (a) brain CT scan, for 
diagnosis of acute thromboembolic and haemorrhagic 
complications, hydrocephalus, oedema, abscess; (b) tran-
scranial Doppler ultrasound to estimate cerebral perfu-
sion and intracranial compliance non-invasively [3]; (c) 
magnetic resonance imaging (MRI) imaging to quantify 
the extent and location of brain damage and for outcome 
prognostication [4]. Neuro-monitoring includes sev-
eral invasive (intracranial pressure, brain oximetry) and 
non-invasive modalities (transcranial doppler, electro-
encephalography [EEG], automated infrared pupillom-
etry). Indications and optimal combination of monitoring 
modalities is dependent on injury type and severity, and 
the expected risk of secondary cerebral damage.
What is new
Automated infrared pupillometry enables the quantita-
tive assessment of basic fundamental neurological tests, 
such as pupillary symmetry and reactivity [5–7]. Multi-
modal monitoring has become central for individualized 
targeted neurocritical care, focused on improving altered 
brain physiology at the bedside [8] and for neuro-prog-
nostication [9, 10].
EEG monitoring of brain function in the comatose patient
What is important
Continuous EEG (c-EEG) is indicated for the man-
agement of refractory status epilepticus. In this set-
ting, when to use continuous versus intermittent EEG 
remains debated [11]. Most epileptic abnormalities can 
be captured using a 2-h recording [12], while c-EEG 
for 24 h or more may be indicated in high-risk patients 
(comatose and prior seizures) [13]. C-EEG may be part 
of multimodal ICU monitoring, e.g. to monitor seda-
tion depth and pharmacological burst-suppression, to 
detect secondary ischaemia, or for coma prognostication 
[14, 15]. There are several barriers to cEEG implementa-
tion, including the requirement for continuous access to 
technicians and neurophysiologists [15] and difficulties 
in data storage. Also, there is a lack of consensus on the 
clinical significance of selected outcome predictive EEG 
patterns that should be prioritized in the ICU setting, i.e. 
non-convulsive seizures, hemispheric asymmetry due 
to evolving ischaemic conditions, and sedation-induced 
EEG suppression. Finally, lack of standardization and reli-
ability, particularly with respect to reactivity to pain [16], 
and the need for an international consensus to define the 
main EEG prognostic features [17] are some of the still 
unsolved questions related to the use of EEG in critically 
ill in comatose patients.
What is new
Spectral analysis (quantitative EEG) and software ena-
bling artefact elimination facilitate availability of EEG 
at the bedside and reduce the risk of reading errors and 
false interpretation. EEG training courses improve the 
accuracy of quantitative EEG reading by general intensiv-
ists, raising hope for future effective implementation in 
daily ICU practice [18, 19].
Assessment of delirious patient
What is important
Brain dysfunction in the ICU patient goes beyond coma-
tose states and includes a wide spectrum of conscious-
ness disorders that characterize delirium states. Delirium 
is defined by a disturbance in attention and awareness 
developing over a short time period, fluctuates during the 
day, and is accompanied by a change in cognition [20]. 
Delirium assessment needs first evaluating the level of 
sedation, e.g. by the Richmond Agitation Sedation Scale 
(RASS), and then utilizing delirium assessment scales 
such as the Confusion Assessment Method for the ICU 
(CAM-ICU) or the Intensive Care Delirium Screening 
Table 1 Care of the injured brain in the general ICU: basic comprehensive aspects
Topic What is important What is new
Management of the comatose patient GCS, brainstem reflexes, FOUR score
Brain imaging (CT scan, MRI)
Multimodal monitoring (ICP, brain oximetry, TCD)
Automated infrared pupillometry
q-EEG
Multimodal monitoring-based individualized therapy
Management of the delirious patient CAM-ICU, ICDSC scores
Minimized targeted sedation
Early active mobilization
ABCDEF, e-CASH bundles
Alternative sedatives (dexmedetomidine)
Prophylactic use of anti-psychotics not effective
Management of ICU-acquired weakness MRC muscle scale, ENMG
Optimize nutrition and glycaemic control
Early active mobilization
Assessment of diaphragmatic dysfunction
Physical (electrical) therapy
Mobilization protocols
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checklist (ICDSC) [21]. Delirium pathophysiology is 
complex, resulting from hypoxic, inflammatory and 
metabolic insults, and may be aggravated or amplified 
by multiple factors. These include non-modifiable fac-
tors (age, co-morbidities, pre-existing cognitive impair-
ment and psychoactive drug use, severity of illness) and 
potentially modifiable factors (renal failure, hyperna-
tremia, hypercapnia, dysglycemia, sedatives, neurotoxic 
antimicrobial agents, immobilization and use of physical 
restraints) [22, 23].
What is new
Emerging evidence established a link between delirium 
and brainstem dysfunction, and particularly autonomic 
nervous system dysfunction and impairment of cholin-
ergic activity [24]. This correlates clinically with the abo-
lition of cough reflex and worse outcome seen in severe 
critically ill patients requiring deep sedation [25]. Accu-
rate evaluation of brainstem function, and the devel-
opment of new scores such as the Brainstem Reflexes 
Assessment Sedation Scale (BRASS) [26], or the use of 
automated pupillometry for quantitative assessment of 
pupillary function [5], may improve delirium assessment 
and outcome prediction. EEG may be helpful for differ-
ential diagnosis and investigating potential contributing 
factors (over-sedation, antibiotic toxicity), as well as in 
predicting prognosis [27, 28].
Sedative strategies and delirium management
Sedative strategies
What is important The general trend in the ICU about 
sedation is “less is more”. Strategies aimed at minimizing 
sedation include [29]:
(1) Daily interruption of sedation, or at least, a daily 
consideration for sedation interruption;
(2) Use of sedation algorithms, to avoid over-sedation;
(3) Analgesia prioritization-based algorithm;
(4) Patient-centred care based on the assessment and 
treatment of specific symptoms (pain, anxiety, delu-
sion), to avoid deep sedation [30].
What is  new Sedative-induced delirium was the most 
frequent delirium subtype in a recent study, and the sub-
type for which prolonged duration of delirium was asso-
ciated with the greatest impact on long-term cognitive 
dysfunction [31]. A strategy of immediate interruption 
of sedation, in ICU patients after major abdominal sur-
gery (mostly with septic shock), translated into reduced 
delirium incidence and hospital length of stay [32]. A 
strategy based on minimizing benzodiazepine is recom-
mended by recent consensus documents [18]. Although 
this may reduce delirium risk in non-severe surgical ICU 
patients, new data showed that delirium prevention using 
anti-psychotics is ineffective in more severe critically ill 
patients [33]. Also, there is currently no data support-
ing the use of monitoring systems, such as the bispectral 
index, to tailor sedation in the critically ill. Continuous 
infusion of dexmedetomidine may accelerate delirium 
recovery [34], while intermittent nightly administration of 
low dose dexmedetomidine promotes sleep and reduces 
delirium [35]; however, this study suffered from a small 
sample size and requires confirmation in larger cohorts. 
In the AWARE randomized multicenter trial, all adult 
patients requiring mechanical ventilation for more than 
48 h were randomized into two groups, based on stand-
ard sedation practices (control; n = 590) versus a sedation 
strategy according to an algorithm which provided a grad-
ual multilevel response to pain, agitation, and ventilator 
dyssynchrony and promotion of the use of alternatives to 
continuous infusion of midazolam or propofol (interven-
tion; n = 584) [36]. Although the use of midazolam and 
propofol was significantly lower in the intervention group, 
90-day mortality was lower, although not significantly 
singnificant (39 vs. 44% in the control group, p = 0.09), in 
the intervention group.
Developing management approaches for delirium
What is important
Delirium management implies the implementation of a 
multistep delirium management bundle, using different 
approaches, such as the e-CASH and ABCDEF bundles 
[20, 37], which include:
(1) Early detection and correction of risk factors (sep-
sis, metabolic and respiratory disturbances);
(2) Control of iatrogenic risk factors (sedation; in par-
ticular, limiting or avoiding benzodiazepines);
(3) Favouring non-pharmacological interventions to 
treat anxiety, pain and sleep privation in order to 
avoid the adverse events associated with psychoac-
tive drugs;
(4) Promoting early active mobilization.
What is  new A multiapproach delirium management 
bundle, coupled with targeted sedation, mechanical venti-
lation weaning strategies, and early mobilization, is effec-
tive in reducing delirium incidence, and even mortality 
[38, 39]. Whether non-pharmacological preventive strat-
egies for anxiety, pain and sleep deprivation may benefit 
cognitive function needs further investigation [40]. In this 
setting, music therapy has gained recent interest in the 
area of critical care [41]. Artificial light is ineffective to 
reduce delirium in the ICU [42].
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ICU‑acquired weakness
Pathophysiology
What is  important? ICU-acquired weakness (ICU-
AW; defined as a generalized hypotonic and symmetrical 
weakness, with sparing of facial muscles, occurring dur-
ing and/or after the ICU stay) is a common and serious 
complication of critical illness [43]. The pathophysiol-
ogy is multifactorial [44], but include severe underlying 
disease, sepsis and/or multiorgan failure, and older age. 
Bed rest may also be an important factor, since it causes 
a significant decrease in strength and cardiorespiratory 
endurance.
What is  new? Animal models are lacking or may fail 
to clarify ICU-AW pathophysiology [45, 46]. Clini-
cal research on ICU-AW during the early phase may 
be limited by coagulation disorders that often ham-
per neurophysiological testing and biopsies Although 
inflammation is consistently increased in experimental 
and clinical studies, infiltration of inflammatory cells 
into the neural and muscular tissue is rarely found [47]. 
Blood glucose control with insulin, targeting normogly-
cemia, and early weaning from mechanical ventilation 
may attenuate ICU-AW [48].
Clinical aspects
What is  important The Medical Research Council 
(MRC) muscle scale is recommended for the diagnosis of 
ICU-AW, with a score below 48 defining ICU-AW [49]. 
Physical examination should be completed by electro-
physiological (electroneuromyography, ENMG), imag-
ing and biology tests to rule out alternative diagnoses, in 
particular when the clinical picture involves asymmet-
ric weakness, pyramidal syndrome, facial involvement, 
ascending/descending weakness, autonomic nervous sys-
tem dysfunction and extra-neurological signs [50].
What is  new The diaphragm is more susceptible to 
systemic inflammation than limb muscles and its struc-
ture and function is rapidly altered after only 36  h of 
mechanical ventilation in humans [51, 52]. ICU-AW and 
diaphragmatic dysfunction share the same risk factors; 
diaphragmatic dysfunction affects the weaning process 
from the ventilator but also survival [53, 54]. ICU-AW 
and diaphragmatic dysfunction have an impact on long-
term morbidity and mortality. Innovative clinical trials 
are needed to examine the effectiveness of early bundle 
strategies that may include electrical stimulation, physi-
cal therapy and optimized nutrition for preventing or 
reducing the occurrence of ICU-AW and diaphragmatic 
dysfunction.
Early mobilization
What is  important Early mobilization and physical 
activity is effective on the short-term in several studies 
[39, 55], although results of long-term outcome studies 
are more controversial [56, 57]. The detrimental physi-
ological effects of restricted mobility on all systems, 
and the benefits of being upright and moving have been 
widely reported. Issues related to early physical activity 
and mobilization of patients in the ICU as a therapeutic 
option including safety, therapy duration and intensity, 
and implementation have only recently been a shared 
focus of interest in the ICU. Accurate assessment of car-
diorespiratory reserve and rigorous screening for other 
factors that could preclude early mobilization is of para-
mount importance [58].
What is new Different (modifiable) barriers for mobili-
zation and rehabilitation were identified by nurses, physi-
otherapists and physicians: they include lack of staff and 
supporting equipment, no protocol, no mobility culture, 
lack of planning and coordination, no ‘champion’ in the 
team, or ‘standing bed rest’ order. A mobilization pro-
tocol, consisting of six levels of early mobilization and 
physical activity (using objective measurements including 
‘basic’ assessment, adequacy score, muscle strength and 
functional performance) could help solving such barriers 
[59].
In a single-center randomized clinical trial enrolling 
more than 300 patients, the addition of early in-bed leg 
cycling plus electrical muscular stimulation (quadriceps 
muscles) to a strategy of standardized early rehabilitation 
(i.e. a weekday progressive multistep program beginning 
with 10 passive range of motion exercises with each limb 
joint applied once every weekday by physiotherapists 
to comatose or sedated patients, followed by passive or 
active exercises and then fully active muscle exercises (i.e. 
transfer to the edge of the bed or to a chair, standing, and 
walking) did not improve global muscle strength at ICU 
discharge [60].
Caring for the injured brain: management 
of specific pathologies
See also Table 2.
Hypoxic‑ischaemic brain injury (HIBI)
What is important
Currently, no pharmacological approach is available 
to treat HIBI [61] and the only recommended inter-
vention with proven efficacy in comatose adults after 
out-of-hospital cardiac arrest with an initial shockable 
rhythm is targeted temperature management (TTM), 
started immediately on patient arrival to the hospital 
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[62]. Pre-hospital cooling, using rapid infusion of large 
volumes of cold intravenous fluid, is not recommended. 
Modern devices with automated temperature retro-
feedback are preferred to keep constant temperature, 
although there is no specific recommendation for a 
precise technique. Neuroprotective strategies include 
maintenance of adequate brain perfusion—by opti-
mizing systemic hemodynamics, blood pressure and 
keeping normal  PaCO2—and oxygenation, by using 
controlled oxygenation  (SaO2 94–98%) and avoiding 
hyperoxia [63]. Neuro-prognostication is based on mul-
timodal assessment, including neurological tests (pupil-
lary reactivity) and electro-physiologic assessment 
(mainly, somatosensory evoked potentials and EEG), 
with clinical decisions taken at least > 72 h, paying spe-
cific attention to exclude potential confounders (resid-
ual sedation, metabolic derangements) and to repeat 
the tests in case of discordant findings [10]. The most 
robust predictors include a bilateral absence of corneal 
and/or pupillary reflexes or N20 waves of short-latency 
somatosensory evoked potentials. These robust predic-
tors have a high specificity, but their sensitivity rarely 
exceeds 50%. If results of most robust predictors are 
normal, a second set of predictors can be tested, such 
as high blood levels of neuron specific enolase (NSE), 
presence of malignant EEG patterns (status epilepticus, 
Table 2 Caring for the injured brain: specific management of severe acute cerebral pathologies
Disease What is important What is new
Hypoxic-ischaemic brain injury In-hospital targeted temperature management 
(TTM)
Optimize blood pressure and ventilatory man-
agement  (SaO2,  CO2)
Multimodal neuro-prognostication
Pre-hospital TTM not effective
Use automated devices for TTM
Precise temperature target undefined
Quantitative tools (pupillometry, MRI) improve 
neuro-prognostication
Immune-mediated encephalitis ≈ 30% of encephalitis are of non-infectious 
origin
Anti-NMDAR encephalitis most common form
Two main patterns in the ICU:
(1) anti-NMDA-R encephalitis (psychiatric symp-
toms, seizures and abnormal movements)
(2), anti-NMDA, GABA-A or LGI-1-R (refractory 
status epilepticus)
CNS vasculitis Two main forms: Primary (primary CNS angitis, 
PACNS) or Secondary to systemic diseases 
(infections, autoimmune vasculitis with or 
without anti-cytoplasmic antibodies (ANCA), 
connective tissue diseases, malignancies, 
lymphoma)
MRI is essential to diagnosis
Treatment of CNS vasculitis requires high-dose of 
steroids; cyclophosphamide and rituximab may 
be added (no consensus)
Refractory status epilepticus Maintain general anaesthesia for at least 24 h
Continuous EEG monitoring
Ketamine is an alternative to barbiturates Novel 
anti-epileptic drugs available (levetiracetam, 
brivaracetam, lacosamide, perampanel, etc.)
Ischaemic stroke Mechanical recanalization and alteplase
Therapeutic time window can be extended 
beyond 12 h
Tenecteplase as alternative to alteplase
Anticoagulation-associated intracerebral haem-
orrhage
Rapid reversal with the use of PCC Idarucizumab for dabigatran reversal
Andexanet-alpha for reversal of other direct oral 
anticoagulants (available in the US only)
Cerebral venous thrombosis Early anticoagulation with heparin Endovascular therapy and/or decompressive 
craniectomy for severe forms
Favourable prognosis in the majority of cases if 
early intervention is applied
Delayed ischaemia after subarachnoid haemor-
rhage
Additional mechanisms other than vasospasm 
play a role
Diagnosis based on the combination of clinical, 
and neuroimaging data
Nimodipine prophylaxis
Management based on the combination of 
medical (BP augmentation) and endovascu-
lar (local vasodilatory drugs ± angioplasty) 
therapies
MMM may help in the diagnosis in comatose 
patients
TBI surgical management Secondary decompressive craniectomy may 
increase dependency in survivors
Individualized multidisciplinary decisions are 
recommended
TBI prognosis IMPACT and CRASH scores Advanced MRI diffusion at least 1 week after 
injury (DWI and DTI)
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burst-suppression, non-reactive background), and signs 
of diffuse HIBI on brain CT or MRI.
What is new
The ongoing international multicentre randomized con-
trolled TTM-2 trial will compare two target tempera-
ture strategies, i.e. 33  °C versus fever control (< 37.8  °C) 
in a large group (n = 1900) of comatose cardiac arrest 
patients and should provide additional robust data to 
available evidence. In recent years, new progress towards 
a better standardization of neuro-prognostic indices has 
been accumulating. Studies adopting the 2013 American 
Clinical Neurophysiology Society guidelines to define 
malignant EEG patterns showed that these patterns are 
not only reproducible with acceptable interrater agree-
ment, but also predict early with both high sensitivity 
and specificity [17]. Automated quantitative pupillom-
etry achieved higher sensitivity and specificity than con-
ventional pupillary assessment to assess poor prognosis 
[7, 64]; in particular, a neurological pupil index (NPI) < 2 
at 24  h after arrest had a specificity of 100% to identify 
patients with unfavourable neurological outcome [64]. In 
patients with prolonged (≥ 7 days) unconsciousness after 
cardiac arrest, measurement of fractional anisotropy of 
the white matter of the brain using diffuse tensor MRI 
imaging, predicted poor neurological outcome with 100% 
specificity and 89% sensitivity [65].
Immune‑mediated encephalitis
What is important
Up to one third of encephalitis is of non-infectious origin 
[66, 67], and in one study 21% of patients with presumed 
infectious encephalitis actually had immune-mediated 
encephalitis [66]. Among immune-mediated encepha-
litis, anti-N-methyl-d-aspartate receptor (NMDA-R) 
encephalitis is the most commonly encountered form. 
The relevant antibody can be detected in the blood and/
or CSF but, despite extensive CSF, EEG and MRI work-
up, immune-mediated encephalitis without identified 
antibodies still exist. First-line therapy includes high-
dose steroids and immunotherapy (IV immunoglobulins 
or plasma exchange). Second-line therapy (rituximab 
or cyclophosphamide) is started in the absence of rapid 
neurological improvement [68, 69]. Careful search of 
neoplastic causes (e.g. ovarian teratoma) is mandatory, 
because surgical removal is indicated in this case [70].
What is new
The recent description of patients with a common clini-
cal presentation in association with ovarian teratoma and 
the identification of specific antibodies directed against 
N-methyl-d-aspartate receptor (NMDA-R) changed our 
view of encephalitis [70]. Since, several new antibodies 
associated to encephalitis are described each year [70]. 
Diagnostic criteria are now available [70]. In the ICU, two 
main patterns are encountered: (1) encephalitis with psy-
chiatric symptoms, seizures and abnormal movements, 
most frequently associated with anti-NMDA-R antibod-
ies, and (2) refractory status epilepticus, associated with 
anti-NMDA-R, GABA-A or LGI-1 antibodies. Impor-
tantly, prognosis is good in the majority of patients [68].
Central nervous system vasculitis
What is important
CNS vasculitis causes inflammation and destruction 
of blood vessel walls affecting brain, spinal cord and/or 
meninges. It is rare (incidence 2.4/million per year) and 
is classified as primary (primary CNS angitis, PACNS) 
or secondary to systemic diseases, including infections 
(bacteria, viruses, parasites and fungi), vasculitis with 
or without the presence of anti-cytoplasmic antibodies 
(ANCA), connective tissue diseases (particularly sys-
temic lupus erythematosus and Sjögren disease) and 
malignancies, including cancers and lymphoma. Clini-
cal manifestations are non-specific and heterogeneous 
(headache, focal motor or sensory abnormalities, cogni-
tive impairment, seizures), and clinical presentation can 
be acute with a feature of stroke involving multiple and 
bilateral vascular territories or chronic and progressive 
with cognitive deficit and psychiatric manifestations. 
CSF reveals aseptic meningitis with modest increased 
cellularity and it may be normal in 20% of cases. MRI 
is essential to diagnosis and reveals multiple ischaemic 
lesions or haemorrhages. A normal MRI associated with 
normal CSF analysis exclude the diagnosis of CNS vascu-
litis. Infectious, neoplastic and autoimmune conditions 
should be ruled out.
What is new
The treatment of CNS vasculitis is an emergency and 
should be related to aetiology. High dose of steroids is 
required in PACNS and for some groups, cyclophospha-
mide should be associated although there is no consen-
sus [71, 72]. The indication of antiplatelet agents is not 
clear and the interest of rituximab and other emergent 
biotherapies is not demonstrated. To conclude, unlike the 
progress of neuroimaging, the diagnosis of CNS remains 
a challenge requiring multimodal approach and a close 
cooperation between specialists (i.e. neurologists, neuro-
radiologists, immunologists…).
Refractory status epilepticus
What is important
Management of status epilepticus (SE) is based on four 
immediate simultaneous actions [71, 74]:
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(1) Confirm diagnosis, eliminate non-epileptic psycho-
genic events, encephalopathies with myoclonus and 
other abnormal movements: video-EEG may help 
in this setting.
(2) Treat systemic consequences of SE and other fac-
tors of cerebral aggression, consequences of treat-
ment, and complications of intensive care.
(3) Treat aggravating factors (e.g. fever).
(4) Ensure sustained interruption of epileptic activity:
(a) 0–5 min: benzodiazepines, renewed if seizures 
last more than 5  min; clonazepam is an effec-
tive alternative to lorazepam and in the absence 
of venous access, intramuscular midazolam is 
an appropriate option.
(b) > 5  min: start an anti-epileptic drug: fosphe-
nytoine, valproate (contraindicated in women 
of childbearing age), phenobarbital, or lev-
etiracetam; defining the optimal treatment 
sequence is debated [75].
(c) > 20–30  min: SE persisting after two appro-
priately selected and dosed parenteral medi-
cations including a benzodiazepine is defined 
as refractory SE (RSE). Coma induction with 
midazolam, propofol then pentobarbital/thio-
pental—and increasingly with ketamine—is 
recommended [76]. Seizures must be clinically 
unquestionable or EEG-proven (non-convul-
sive status post-generalized status); therefore, 
EEG is an integral part of the management of 
RSE. Guidelines recommend obtaining the sup-
pression of electrographic seizures or aiming 
for burst-suppression for at least 24  h before 
gradual reduction in IV anaesthetics [73].
SE persisting for > 24 h after the onset of general anaes-
thesia is defined as super-refractory SE (SRSE) [76]. The 
treatment remains empiric. An immunological cause 
must be ruled out and treated early. Although SRSE has 
a poor prognosis, some patients may recover even in pro-
longed cases. Advice by and/or transfer to centres with 
specific neurology expertise are advisable [77].
What is new
Novel anti-seizure medications (e.g. levetiracetam, bri-
varacetam, lacosamide, perampanel), with a better safety 
and pharmacokinetic profile, hold promise for the treat-
ment of RSE. Further studies are required to clarify the 
indications and optimal use of such novel agents [78]. 
While avoidance of fever is recommended in RSE, thera-
peutic hypothermia (32–34 °C for 24 h) does not confer 
any additional benefit [79].
Acute ischaemic stroke
What is important
Mechanical thrombectomy with intravenous alteplase 
(rtPA) is the current gold standard to improve neuro-
logical outcomes of acute ischaemic stroke consecutive 
to large vessel occlusion of the anterior circulation (i.e. 
internal carotid and middle cerebral arteries) based on 
six randomized controlled trials showing the superiority 
of such strategy over rtPA alone (number needed to treat 
2.6) [80]. The benefit of mechanical thrombectomy was 
the most important for the oldest patient over 80  years 
old and those with the most severe strokes. The thera-
peutic window for mechanical thrombectomy initially 
established at 6  h after symptoms onset has moved to 
24 h since the recent publication of two randomized tri-
als showing the benefit of endovascular therapy in highly 
selected patients with multimodal imaging [81].
What is new
Trials are currently ongoing to address the benefit of 
mechanical thrombectomy alone versus mechanical 
thrombectomy in association with intravenous alteplase. 
Tenecteplase may be associated with higher recanaliza-
tion rates compared to alteplase in patients with large 
vessel occlusions [82, 83]. The best strategy for patient 
transfer (i.e. “drip and ship” thrombolysis at a local stroke 
unit and transfer to a comprehensive stroke centre for 
mechanical thrombectomy versus “mother ship” direct 
transfer to the comprehensive stroke centre) remains to 
be established.
Management of acute ischaemic stroke in patients treated 
with oral anticoagulants
Systemic thrombolysis with rtPA is contra-indicated in 
patients treated with anticoagulants, including direct oral 
anticoagulants (DOAC; including dabigatran, rivaroxa-
ban, apixaban, and edoxaban). Idarucizumab, the specific 
antidote of dabigatran, induces immediate normalization 
of coagulation, without intrinsic thrombotic effect. Based 
on expert consensus, the use of rtPA is proposed for dab-
igatran-treated patients facing ischaemic stroke immedi-
ately after dabigatran reversal [84]. Rapid measurement 
of dabigatran concentration may improve the selection of 
patients that may benefit from reversal. Such strategy is 
not recommended with other DOAC.
Anticoagulant associated brain haemorrhage
What is important
Spontaneous oral anticoagulation-related intracerebral 
haemorrhage is associated with larger haematoma vol-
umes and increased rates of haematoma enlargement, 
leading to higher mortality rates. Therefore, prevention 
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of secondary haematoma expansion is an important goal, 
based on urgent reversal of anticoagulation. Whereas 
appropriate reversal of vitamin K antagonists (VKA) is 
associated with a decrease in mortality, whether reversal 
of DOAC may improve outcome has never been demon-
strated [85].
What is new
Management of DOAC reversal is evolving: activated or 
non-activated prothrombin concentrates were initially 
recommended, despite limited data on their safety and 
efficacy. Andexanet-alpha, the specific antidote to factor 
Xa-inhibitors, is not marketed yet in Europe and raises 
concerns regarding its potential thrombotic risk. Idaru-
cizumab, the specific antidote of dabigatran, is currently 
available. In a mouse model of dabigatran-related ICH, 
idarucizumab not only prevented haematoma expansion 
but also reduced mortality [86]. Therefore, as for VKA, 
guidelines recommend urgent reversal in patients with 
DOAC-related ICH, irrespective of the agent [87]. The 
role of surgery remains controversial and haematoma 
removal should be reserved only for salvageable patients 
(i.e. young age with rapid deterioration) with clinical and/
or CT signs of brain herniation.
Cerebral venous thrombosis
What is important
Cerebral venous thrombosis is an uncommon cause of 
stroke (< 1% of all causes). At the acute phase, treatment 
includes management of the associated condition (infec-
tion, inflammatory conditions…), anticoagulation with 
low molecular weight or unfractionated heparin, treat-
ment of intracranial hypertension, prevention of recur-
rent seizures and headache relief. Prognosis is generally 
good: mortality is below 5%, with only 15% of the patients 
remaining dependent [88].
What is new
In severe cases, decompressive surgery (i.e. hemicraniec-
tomy and/or haematoma drainage) is lifesaving and 
often results in good functional outcome, irrespective 
of age, coma, aphasia, bilateral lesions, or non-reactive 
mydriasis [89]. Endovascular intervention is an alterna-
tive option for patients with severe forms on admission 
or with neurological deterioration despite the appropri-
ate use of anticoagulation, especially in patients with 
thrombosis of the cerebral deep venous system and 
without large expanding hemispheric lesions [90]. The 
publication of the TOACT (Thrombolysis or anticoagu-
lation for cerebral venous thrombosis) trial is expected; 
this randomized trial comparing endovascular treatment 
(thrombolysis with urokinase or rtPA and/or thrombec-
tomy of any type) versus heparin will provide additional 
evidence on the best therapeutic strategy (clinical trials.
gov NCT01204333).
Delayed ischaemia after subarachnoid haemorrhage
What is important
About 30% of patients suffering from aneurysmal suba-
rachnoid haemorrhage (SAH) develop delayed cerebral 
ischaemia (DCI), defined as the occurrence of focal 
neurological impairment (such as hemiparesis, aphasia, 
apraxia, hemianopia, or neglect), or a decrease of at least 
2 points on the Glasgow Coma Scale, with an acute onset 
and not attributed to other surgical or medical conditions 
[91]. DCI pathophysiology is complex; although the pres-
ence of cerebral vasospasm is often associated with the 
occurrence of this condition, DCI may also result from 
microvascular dysfunction, neuro-inflammation, cortical 
spreading depolarization or an imbalance between vaso-
active substances, in the absence of narrowing of large 
intracranial vessels. Importantly, DCI, but not cerebral 
vasospasm, is an independent determinant of morbidity 
and mortality in SAH patients. Oral nimodipine is rec-
ommended for prophylaxis after SAH, despite its effect is 
independent from the occurrence of vasospasm, it is sup-
ported by very old and questionable evidence, and there 
are no data on DCI.
What is new
Drugs, such as intravenous magnesium or endothelin-
receptor antagonists, failed to provide any benefit on the 
neurological outcome of SAH patients, despite reduc-
ing vasospasm [92]. One limitation in the management 
of DCI is the lack of standardized neuro-monitoring for 
early detection and an appropriate therapy besides the 
use of vasopressors to increase mean arterial pressure. 
Concerning neuro-monitoring, the use of transcranial 
doppler (TCD) and continuous electro-encephalography 
(cEEG) in clinically evaluable patients may help to detect 
cerebral disturbances and immediately perform brain 
imaging (i.e. brain CT angiography, CTA—brain CT per-
fusion, CTP) to exclude the presence of clinically relevant 
cerebral vasospasm (i.e. resulting in brain hypoperfu-
sion). In comatose patients, the combination of TCD/
cEEG with brain tissue oxygen monitoring or microdialy-
sis may effectively detect early DCI when clinical exami-
nation is unreliable [93, 94]. If DCI is related to cerebral 
vasospasm and vasopressor therapy does not improve 
clinical conditions or brain oxygenation, alternative 
interventions may include endovascular therapies (i.e. 
intra-arterial nimodipine or milrinone, balloon angio-
plasty, intra-carotid continuous infusion of vasodilators), 
often combined with systemic inotropic therapy.
Page 9 of 13Oddo et al. Ann. Intensive Care            (2019) 9:47 
Clinical dilemmas: surgical decompression
What is important
Decompressive craniectomy (DC), i.e. surgical removal 
of a part of cranial vault with dura mater opening, is 
extremely effective in reducing brain herniation and 
intracranial pressure. This procedure is lifesaving, with 
controversial results on neurological recovery. In patients 
with large ischaemic stroke, DC decreases death rate and 
improves functional status. However, the proportion of 
patients with good neurological recovery remains low 
[95, 96]. In stroke patients aged < 60 years with unilateral 
MCA infarctions who deteriorate neurologically within 
48  h despite medical therapy, DC reduces mortality by 
close to 50%, with 55% of the surgical survivors achiev-
ing moderate disability (able to walk) or better (modified 
Rankin scale, mRS score 2 or 3) and 18% achieving inde-
pendence (mRS score 2) at 12 months, while for patients 
> 60 years of age DC reduces mortality by close to 50%, 
with 11% of the surgical survivors achieving moderate 
disability (able to walk [mRS score 3]) and none achiev-
ing independence (mRSscore ≤ 2) at 12  months. In two 
clinical trials on patients with severe head trauma, DC 
was effective in reducing mortality [97, 98]. However, the 
rate of head trauma patients with severe disability and/
or vegetative state was significantly higher in the DC 
group, as compared to controls. However, both the stud-
ies above have limitations; one trial used only bi-frontal 
DC, selected only patients with diffuse brain injury and 
in the very early phase of therapy, when additional less 
invasive interventions could have been attempted [97]. In 
the second trial, 37% of controls also underwent delayed 
DC as salvage procedure, which produced a significant 
crossover between the study groups [98].
What is new
Despite the Brain Trauma Foundation recommends 
against bi-frontal DC [99], large DC, either unilateral or 
bilateral, might still be considered in some patients, such 
as those with neurological deterioration between admis-
sion and re-examination (i.e. secondary brain injury), as 
this would exclude severe primary injury and brainstem 
lesions [100, 101]. As such, DC remains a procedure with 
uncertain benefits on neurological recovery that deserves 
a multidisciplinary and rational approach, based on clini-
cal trajectories and imaging. As ethical concerns are at 
stake with this procedure, relatives should be involved in 
the decision process.
Clinical dilemmas: outcome prediction after head trauma
What is important
The International Mission on Prognosis and Analysis of 
Clinical Trials (IMPACT) and the Corticosteroid Rand-
omization after Significant Head Injury (CRASH) scores 
have been developed from large datasets and were exter-
nally validated to predict mortality and neurological 
outcome after traumatic brain injury (TBI) at 6 months 
[102–104]. Nevertheless, these scores are limited because 
functional recovery may continue for at least 18 months 
following TBI in some patients and because of the large 
heterogeneity in outcome prediction for an individual 
patient.
What is new
Advanced magnetic resonance imaging (MRI)—with the 
use of susceptibility-weighted-imaging (SWI), diffusion-
weighted-imaging (DWI) and high-definition-fibre-
tractography (HDFT)—improves outcome prediction, 
despite the lack of evidence supporting its routine clinical 
use [105, 106]. MRI diffusion tensor imaging (DTI) and 
fractional anisotropy (FA) assess white matter integrity 
and are important in predicting outcome [107, 108]. The 
Coma Score was developed using MRI-DTI to predict 
1-year outcome of patients unresponsive to simple orders 
after HIBI between day 7 and 45 after initial injury [65]; 
current ongoing research is evaluating this approach to 
predict TBI outcome. In a cohort of 105 comatose TBI 
patients, the area under the curve of the DTI score to 
predict poor outcome was 0.84 (95% CI: 0.75–0.91) [109].
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